Back to Search
Start Over
Measurable residual disease-guided therapy in intermediate-risk acute myeloid leukemia patients is a valuable strategy in reducing allogeneic transplantation without negatively affecting survival.
- Source :
-
Haematologica [Haematologica] 2023 Oct 01; Vol. 108 (10), pp. 2794-2798. Date of Electronic Publication: 2023 Oct 01. - Publication Year :
- 2023
Details
- Language :
- English
- ISSN :
- 1592-8721
- Volume :
- 108
- Issue :
- 10
- Database :
- MEDLINE
- Journal :
- Haematologica
- Publication Type :
- Editorial & Opinion
- Accession number :
- 37021540
- Full Text :
- https://doi.org/10.3324/haematol.2022.282639